Conditions: Hepatitis, Chronic Hepatitis C Virus
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: no

Brief summary:
Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.

Detailed description:

Arms:
arm 1: None arm 2: Dose study drug in subjects who have previously failed to respond to interferon based therapies

Interventions: intervention 1: Small Molecule Agent (PF-868554) intervention 2: Small Molecule Agent (PF-868554)
Intervention descriptions: intervention 1: Study drug will be administered 700mg BID in the fed state for three days. intervention 2: Study drug will be given 450mg BID for a duration of 10 days.

Protocol document: